Core Viewpoint - Biophytis has signed a co-development agreement with AskHelpU to evaluate the efficacy of its lead drug candidate BIO101 for treating Amyotrophic Lateral Sclerosis (ALS) in China [1][2][3] Company Overview - Biophytis SA is a clinical-stage biotechnology company focused on developing treatments for age-related diseases, with its lead drug candidate BIO101 targeting muscular diseases, respiratory diseases, and metabolic disorders [5] - The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil, and its shares are listed on Euronext Growth Paris [5] Partnership Details - The agreement with AskHelpU aims to leverage Biophytis' expertise in drug development and AskHelpU's knowledge of ALS, utilizing top Chinese universities and research laboratories for experiments [3] - AskHelpU, founded by Cai Lei, is the largest ALS patient association in China, connecting over 15,000 individuals affected by neurodegenerative diseases [6] Market Context - ALS has a global prevalence of 4.1 to 8.4 patients per 100,000 inhabitants, with approximately 200,000 patients in China, representing a significant market for new treatment development [4] - The partnership signifies a unique opportunity for Biophytis to expand the potential applications of BIO101, which is also in development for other conditions such as sarcopenia and obesity [2][3]
Biophytis and AskHelpU Sign a Co-Development Agreement in Rare Neuromuscular Diseases in China